Novo Nordisk Stock Up Over 2% Premarket Today — Thanks To OpenAI Tie-Up

• The deal will use AI to analyze complex datasets, identify drug candidates and shorten development timelines from research to patient care.
• Novo plans pilot programs across R&D, manufacturing and commercial operations, with full integration expected by year-end.
• OpenAI will also support workforce AI training and help improve efficiency across the supply chain and distribution.

Shares of Novo Nordisk (NVO) rose more than 2% in premarket trading on Tuesday after the Ozempic and Wegovy maker announced a partnership with OpenAI to accelerate drug discovery for obesity and diabetes using advanced AI.

NVO stock jumped over 1% on Monday, logging its second straight session of gains.

Novo Nordisk Expands AI Push With OpenAI Deal

The Danish drugmaker said the collaboration will apply advanced AI tools to analyze complex datasets, identify promising drug candidates and shorten the time required to move therapies from research into patient care.

Novo said it will launch pilot programs across research and development, manufacturing and commercial operations, with full integration expected by the end of this year. The company also said OpenAI will support workforce upskilling and AI literacy across the company’s global operations. 

AI capabilities will additionally be deployed to improve efficiency across manufacturing, supply chain, distribution and corporate functions as part of a broader digital transformation push already underway with multiple technology and research partners.

The deal has been structured with data protection safeguards, governance oversight and human supervision to ensure ethical and compliant deployment of AI tools, Novo said. 

“Integrating AI in our everyday work gives us the ability to analyze datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever,” CEO Mike Doustdar said in a statement. 

OpenAI CEO Sam Altman said: “This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.” For OpenAI, the deal comes as the ChatGPT developer races rival Anthropic to a public listing, following a recent fundraising round that valued the company at $852 billion.

Novo Steps Up GLP-1 Race With Eli Lilly

Novo's announcement efforts by Novo to strengthen its obesity portfolio as competition intensifies with Eli Lilly in the fast-growing GLP-1 market. Last week, the company confirmed nationwide availability of its higher-dose Wegovy 7.2 mg injection across more than 70,000 U.S. pharmacies. 

The new formulation delivered the highest weight loss observed with Wegovy in clinical testing, with 89% of participants achieving at least 5% weight loss at 72 weeks, compared with 38% on placebo, according to late-stage trial data cited by the company.

Novo Nordisk has also introduced new self-pay subscription pricing programs for Wegovy through telehealth platforms, including Ro, WeightWatchers and LifeMD, offering discounts of up to nearly 30% as the company seeks to widen access and defend market share against Lilly’s rival obesity drug Zepbound.

The company launched an oral weight-loss pill in January as it looks to regain momentum in the obesity treatment segment. However, Novo now expects 2026 adjusted sales growth of 5% to 13% at constant exchange rates, driven by pricing pressure and competition.

How Do Retail Traders Feel About NVO?

On Stocktwits, retail sentiment for NVO improved to ‘neutral’ from ‘bearish’ levels a day ago amid ‘normal’ message volume.

One user said, “Novo Nordisk is basically giving its lab coats a 'brain upgrade' from OpenAI to find new drugs faster than you can say 'semaglutide,’ proving that even multi-billion dollar pharma giants aren't immune to the ‘AI or die’ trend.”

Another user said, “Never thought I’d see an openai partnership here.”

NVO stock has declined 30% over the past year. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision